BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38234179)

  • 1. Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer.
    Wasifuddin M; Ilerhunmwuwa NP; Becerra H; Hakobyan N; Wasifuddin S; Asadi HA; Wang JC
    J Chemother; 2024 Jan; ():1-6. PubMed ID: 38234179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
    Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
    Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
    Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurbinectedin in the treatment of relapsed small cell lung cancer.
    Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
    Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
    Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
    Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurbinectedin: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(13):1345-1353. PubMed ID: 32816202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
    Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T
    Intern Med J; 2024 Feb; ():. PubMed ID: 38369719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin.
    Kauffmann-Guerrero D; Huber RM
    Lung Cancer (Auckl); 2020; 11():27-31. PubMed ID: 32184690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
    Shinn LT; Vo KA; Reeves DJ
    Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
    Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
    Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
    Fudio S; Pérez-Ramos L; Asín-Prieto E; Zeaiter A; Lubomirov R
    Front Oncol; 2023; 13():1152371. PubMed ID: 37397388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
    Das M; Padda SK; Weiss J; Owonikoko TK
    Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
    Patel S; Petty WJ; Sands JM
    Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
    Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
    Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
    Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
    Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
    Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
    Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.